You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company said it will use the financing to support the commercialization of its automated biological testing platform for academic and clinical research.
Revenues during the quarter were $716.3 million, beating Wall Street estimates, while full year 2019 revenues totaled $2.41 billion.
The company, which recently signed a licensing agreement with Horizon Discovery, just raised $45 million in a Series B financing round.
The rise of new protein analysis techniques have some questioning whether mass spec will in coming years retain its dominant position within proteomics.
The 2010s saw major strides made through several large-scale initiatives aimed at mapping the human proteome and developing approaches for clinical work.
The funds will support the companies' efforts to develop tests for predicting NSCLC patients' response to immunotherapy.
Researchers' picks range from emerging tools like deep learning to fundamental issues like false discovery rates and infrastructure for mass spec data sharing.
Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.
Analysts expect the South-San Francisco-based company to report $30.2 million in revenues for Q4 and $116.4 million in full-year 2019 revenues.
A survey asking researchers for their thoughts on the key developments in the field turned up applications ranging from clinical to structural.
Atreca will use Serimmune's Serum Epitope Repertoire Analysis (SERA) platform to identify the targets of anti-cancer antibodies Atreca is developing.
Data privacy has been an issue in genomics for some time, but new regulations and improved technology could force proteomics to confront it, as well.
The additional funds follow the $25 million that the company announced in May 2019, bringing the total figure for the round to $45 million.
With new instruments and workflows able to quantify thousands of proteins in as little as five minutes, 2019 was the year proteomics cracked its throughput problem.
Researchers from France's DreamPore and their collaborators used a nanopore to distinguish between 15 of the 20 proteinogenic amino acids.
The company said that it plans to use the funds to develop and commercialize its Proteograph proteomics platform for research and clinical applications.
Researchers identified 10 protein-based tumor subtypes across five cancer types, including subtypes representing immune cell features in the tumor microenvironment.
The firm completed financing actions raising around $1.2 billion in funds that it plans to use to provide financial flexibility and fund corporate objectives.
They collected data on 59 features of more than 100,000 phosphosites and combined those features into a score predictive of a site's functional importance.
According to its developers, the software allows for the quantification several hundred proteins in five-minute DIA analyses of undepleted plasma.
Nature News reports that genomics is being applied to trace and try to prevent additional COVID-19 waves.
Rady's Children Hospital and San Diego County are teaming up to test pediatric patients and their families for COVID-19 to gauge the spread of the virus locally, according to the San Diego Union-Tribune.
Wildlife managers aim to boost the genetic diversity of Mexican gray wolves by placing captive-born foster pups into packs with similarly aged wild pups, the Mercury News reports.
In Science this week: Genetic Probability tool identifies likely diagnoses in 45 percent of inflammatory arthritis cases, and more.